User:Mr. Ibrahem/Flecainide
 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | /flɛˈkeɪnaɪd/ flek-AY-nyde |
| Trade names | Tambocor, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608040 |
| Pregnancy category |
|
| Drug class | Ic antiarrhythmic[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Protein binding | 40% |
| Metabolism | CYP2D6 (limited) |
| Elimination half-life | 20 hours (range 12–27 hours) |
| Excretion | Kidney |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C17H20F6N2O3 |
| Molar mass | 414.348 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
  (what is this?) (verify) | |
Flecainide is a medication used to prevent and treat abnormally fast heart rates.[1] This includes ventricular and supraventricular tachycardias.[1] Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments.[1] Its use does not decrease a person's risk of death.[1] It is taken by mouth or injection into a vein.[1][3]
Common side effects include dizziness, problems seeing, shortness of breath, chest pain, and tiredness.[1] Serious side effects may include cardiac arrest, arrhythmias, and heart failure.[1] It may be used in pregnancy, but has not been well studied in this population.[3][4] Use is not recommended in those with structural heart disease or ischemic heart disease.[1] Flecainide is a class Ic antiarrhythmic agent.[1] It works by decreasing the entry of sodium in heart cells, causing prolongation of the cardiac action potential.[1]
Flecainide was approved for medical use in the United States in 1985.[1] It is available as a generic medication.[3] A month supply in the United Kingdom costs the NHS about £7.68 as of 2019.[3] In the United States the wholesale cost of this amount is about 18.60 USD.[5] In 2017, it was the 289th most commonly prescribed medication in the United States, with more than one million prescriptions.[6][7]
References[edit]
- ^ a b c d e f g h i j k l "Flecainide Acetate Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 7 April 2019.
- ^ "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 8 September 2020.
- ^ a b c d British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 103. ISBN 9780857113382.
- ^ "Flecainide (Tambocor) Use During Pregnancy". Drugs.com. Retrieved 7 April 2019.
- ^ "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019.
- ^ "The Top 300 of 2020". ClinCalc. Retrieved 11 April 2020.
- ^ "Flecainide Acetate - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.